Mode
Text Size
Log in / Sign up

Patient Questions

Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.

Cardiology

What lab factor helps predict coronary lesions in children with Kawasaki disease?

Routine lab indicators like C-reactive protein and erythrocyte sedimentation rate help predict coronary artery lesions in children with Kawasaki disease.

Diabetes & Endocrinology

Do GLP-1 agents address eating disorders through appetite and gut-brain signaling pathways?

GLP-1 agents address eating disorders by targeting appetite and gut-brain signaling pathways that regulate food reward and intake.

Neurology

How do doctors predict the risk of post-stroke cognitive impairment after a stroke?

Doctors predict post-stroke cognitive impairment risk using clinical prediction models that combine factors like age, sex, blood biomarkers, and brain imaging findings.

Do high homocysteine or uric acid levels cause post-stroke cognitive impairment?

High homocysteine levels are linked to post-stroke cognitive impairment, while the role of uric acid is mixed; neither is proven to directly cause it.

Nephrology

Do complement pathways play a role in kidney diseases affecting my transplant?

Yes, complement pathways are involved in kidney transplant rejection, including antibody-mediated rejection, and may be targeted for therapy.

Cardiology

Can erythropoiesis-stimulating agents help adults with chronic heart failure and anaemia?

Erythropoiesis-stimulating agents (ESAs) reduce total heart failure hospitalizations and improve exercise tolerance in adults with chronic heart failure and anaemia, but do not…

Hematology

Can the FDA-approved drug Xarelto be used to treat Deep Vein Thrombosis?

Yes, Xarelto (rivaroxaban) is FDA-approved for treating deep vein thrombosis (DVT) and reducing the risk of recurrent DVT.

Cardiology

Does Xarelto help prevent stroke in patients with nonvalvular atrial fibrillation and Deep Vein Thrombosis?

Yes, Xarelto (rivaroxaban) is FDA-approved to reduce stroke risk in nonvalvular atrial fibrillation and to treat deep vein thrombosis, making it effective for patients with both…

Cardiology

What are the main themes in coping experiences for chronic heart failure patients and caregivers?

Coping experiences for CHF patients and caregivers center on differing views of illness, emotional exhaustion, strained relationships, and a need for support to find new meaning.

Cardiology

Can an apical sparing ratio help detect cardiac amyloidosis in my heart?

Yes, the apical sparing ratio (ASR) can help detect cardiac amyloidosis, but it is not perfect—it has moderate accuracy and should be used alongside other tests.

Cardiology

Do alternative loop diuretics reduce hospitalizations for patients with chronic heart failure?

No, alternative loop diuretics (torsemide, azosemide, piretanide) do not reduce hospitalizations compared to furosemide in chronic heart failure, based on a systematic review of…

Cardiology

Which imaging tests are best for distinguishing cardiac amyloidosis from other heart issues?

Cardiac MRI with contrast and bone scintigraphy are the best tests for distinguishing cardiac amyloidosis from other heart issues, with echocardiography as a useful first…

Can education help lower my risk of Deep Vein Thrombosis after orthopedic surgery?

Yes, education can help lower your risk of DVT after orthopedic surgery. A meta-analysis found that patients who received education had about half the risk of developing DVT…

Cardiology

Does taking Qishen Yiqi dropping pills plus Western medicine improve chronic heart failure efficacy?

A 2024 trial found that adding Qishen Yiqi dropping pills to standard Western medicine improved clinical effectiveness and heart function in chronic heart failure patients.

What clinical remission definition do experts suggest for severe asthma?

Experts suggest clinical remission in severe asthma means no exacerbations, no oral corticosteroids, good symptom control, and stable or optimal lung function.

Pulmonology & Critical Care

Does biologic therapy improve asthma control for patients with severe asthma?

Yes, biologic therapy significantly improves asthma control for patients with severe asthma, reducing exacerbations and improving symptoms and lung function.

Pulmonology & Critical Care

Is tezepelumab a treatment option for severe asthma patients with low inflammation?

Yes, tezepelumab is approved for severe asthma regardless of inflammation type, including low type 2 inflammation, though benefit may be smaller in these patients.

What are the lung function goals for patients with severe asthma?

Lung function goals for severe asthma focus on achieving optimal individual FEV1 and maintaining stability, rather than normal values, as part of clinical remission.

Pulmonology & Critical Care

Can switching asthma biologics help reduce severe asthma attacks?

Switching asthma biologics often reduces severe asthma attacks, improves lung function, and lowers the need for oral steroids, though the specific benefit depends on a patient's…

Do new therapies help Follicular Lymphoma patients who progress within 24 months?

Yes, new therapies like CAR T cells, bispecific antibodies, and targeted drugs show high response rates in follicular lymphoma patients who progress within 24 months.

Does adding R-CVP after radiotherapy improve survival for early-stage Follicular Lymphoma?

Adding R-CVP after radiotherapy significantly improves progression-free survival in early-stage follicular lymphoma, but overall survival benefit is not yet proven.

Oncology

Can Revlimid be used to treat Follicular Lymphoma?

Yes, Revlimid (lenalidomide) is FDA-approved for previously treated follicular lymphoma, specifically in combination with rituximab.

Oncology

What are the safety results for fixed-duration subcutaneous mosunetuzumab in Follicular Lymphoma?

Fixed-duration subcutaneous mosunetuzumab shows a favorable safety profile with lower rates of severe immune-related adverse events compared to the intravenous version in…

Oncology

What is the response rate for abexinostat in relapsed Follicular Lymphoma?

Abexinostat shows a 69.5% objective response rate in relapsed follicular lymphoma, based on a phase 2 trial.

How this works

We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.

This is not medical advice. Always speak with your own doctor before making decisions about your health.